Human Longevity Stock

www.humanlongevity.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $91.95MM

Human Longevity is a biotechnology company which offers genomics and data analytics solutions to healthy individuals. This company was founded by J. Craig Venter Ph.D, Peter Diamandis, and Robert Hariri Ph.D in 2013 and is headquartered in San Diego, CA. Human Longevity’s platform includes the Health Nucleus, a comprehensive health assessment that combines whole-gene sequencing, advanced imaging, and other diagnostics aiming to identify potential health risks and develop personalized longevity plans.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Human Longevity, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Private Market Pricing DetailsValuation & Financings

Human Longevity Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Human Longevity Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/21/2024 Series B-2 $7.9MM $xx.xx $185.79MM TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust
Price per Share
$xx.xx
Shares Outstanding
30,850,126
Liquidation Pref Order
1
Liquidation Pref As Multiplier
3.0x
Conversion Ratio
3.0x
Dividend Rate
9.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust
08/21/2024 Series B-1 $32MM $xx.xx $185.79MM TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust
Price per Share
$xx.xx
Shares Outstanding
102,860,812
Liquidation Pref Order
1
Liquidation Pref As Multiplier
3.0x
Conversion Ratio
3.0x
Dividend Rate
9.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust
11/06/2019 Series A-2 $34.06MM $xx.xx $50.4MM Emerging Technology Partners
Price per Share
$xx.xx
Shares Outstanding
133,034,522
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Emerging Technology Partners
11/06/2019 Series A-1 $18MM $xx.xx $50.4MM Emerging Technology Partners
Price per Share
$xx.xx
Shares Outstanding
7,964,602
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.2x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Emerging Technology Partners

Human Longevity investors also invested in these private companies

Leadership & Board

Leadership

J. Craig Venter Ph.D
Co-Founder & Chief Scientific Advisor
Robert Hariri Ph.D
Co-Founder
Peter Diamandis MD
Co-Founder
David Karow MD, Ph.D
President & Chief of Radiology
Julie Chen MD
Chief Medical Officer & San Francisco Medical Director
Wei Zhou Ph.D
Chief Technology Officer
James Dickey
Chief Commercial Officer
James Hu
Chief Administrative Officer

Board

Brett Blundy
BB Retail Capital
Helmut Schuehsler Ph.D
TVM Capital Healthcare Partners

Human Longevity stock FAQs

plusminus

Can you buy Human Longevity stock?

As Human Longevity is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Human Longevity, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Human Longevity stock?

To invest in a private company like Human Longevity through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Human Longevity stock?

Yes, you may sell the Human Longevity stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Human Longevity stock?

If you hold private company shares of Human Longevity – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Human Longevity on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Human Longevity a public company?

No, Human Longevity is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Human Longevity’s stock price?

Human Longevity is a privately held company and therefore does not have a public stock price. However, you may access Human Longevity private market stock price with Forge Data.
plusminus

What is Human Longevity’s stock ticker symbol?

Human Longevity does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Human Longevity’s news and media highlights

Human Longevity, Inc. (HLI), with over 10 years as a longevity focused technology company, today announced the completion of an oversubscribed $39.8M Series B round led by TVM Capital Healthcare with participation from new and existing investors, including Panacea Venture and Emerging Technology Partners. The funding will be used to invest in HLI's artificial intelligence health risk and recommendation platform, new longevity focused technologies and services, and new expansion sites globally. Founded in 2013, with a group of pioneers in the precision medicine field, HLI has made significant research and development progress in the longevity field.
Human Longevity has spun out Simplify Genomics to provide genomic interpretation services and software. Simplify Genomics launched Smart Genome, a platform developed at Human Longevity, to analyze and report on genomic data. The company aims to differentiate itself through its database, automation, and search capabilities.
The article discusses the emerging longevity therapeutics market, highlighting recent scientific advances enabling research into treating aging. It notes the potential for advanced therapeutics to expand healthspans if recognized as a priority. The article recommends investors focus on advanced therapeutics as the entry route into the longevity market.
The genome sequencing company plans to go public through a merger with Freedom Acquisition I Corp that values the combined company at about $1B.
Updated on: Nov 11, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.